Introduction
Cell-surface retention sequence (CRS) binding protein-1 (CRSBP-1), a membrane glycoprotein, was identified by its ability to interact with oligopeptides containing the CRS motifs of VEGF-A 165 and PDGF-BB in human SK-Hep cells and bovine liver plasma membranes [1] . The CRS motifs of VEGF-A 165 and PDGF-BB contain clustered basic amino acid residues (Arg, Lys and His) [2] [3] [4] [5] . CRSBP-1 interacts with PDGF-BB in simian sarcoma virus (SSV)-transformed cells which express both CRSBP-1 and the autocrine sis oncogene product (PDGF-BB) [6] . CRSBP-1 is identical to lymphatic vessel endothelial hyaluronic acid (HA) receptor-1 (LYVE-1) [7] [8] [9] . The primary localization of LYVE-1 in lymphatic endothelium implies the likely importance of the multiple ligand (CRS-containing growth factors/cytokines and HA) binding activity of CRSBP-1/LYVE-1 in regulating the function of lymphatic vessels.
To determine the in vivo role of CRSBP-1, we generated CRSBP-1-null (CRSBP-1 À/À ) mice [10] . These mice are macroscopically normal but exhibit distended lumens of lymphatic vessels and constitutively increased transit of fluid from the interstitial space into lymphatic vessel lumens (termed interstitial-lymphatic transit). CRSBP-1 ligands are capable of increasing interstitial-lymphatic transit of fluid in wild-type mice but not in CRSBP-1 À/À mice. These results suggest that CRSBP-1 and its ligands regulate the function of lymphatic intercellular junctions. They also support our hypothesis that the CRSBP-1-null mutation and binding of CRSBP-1 by its cognate ligands cause opening of lymphatic intercellular junctions, resulting in increased interstitial-lymphatic transit [10] .
To determine the molecular mechanism by which CRSBP-1 and its ligands regulate the opening of lymphatic intercellular junctions, we investigated the effects of CRSBP-1 ligands on tyrosine phosphorylation and internalization of VE-cadherin, which forms button-like structures at lymphatic intercellular junctions [11] in LECs. We hypothesized that the CRSBP-1-null mutation and binding of CRSBP-1 by its cognate ligands would result in loss and ''unbuttoning'' of VE-cadherin-mediated buttons, respectively, leading to opening of lymphatic intercellular junctions [10, 12] . We found that CRSBP-1 ligands (PDGF-BB, VEGF-A 165 , PDGF peptide, VEGF peptide and HA) stimulate tyrosine phophorylation of PDGF b-type receptor/b-catenin/VE-cadherin, internalization of VE-cadherin and cellular contraction in LEC monolayers [12] . This leads to opening of lymphatic intercellular junctions. These CRSBP-1 ligand-stimulated effects are abolished in LECs treated with a PDGF b-type receptor (PDGFbR) kinase inhibitor or CRSBP-1 siRNA [12] . To determine the role of CRSBP-1 in ligand-stimulated LEC contraction, we investigated the subcellular localization of CRSBP-1 in LECs, which include primary human dermal LECs (HDLECs) and SVEC4-10 cells (a LEC-like cell line), treated with CRSBP-1 ligands. CRSBP-1 [9, 12] and by indirect immunofluorescence staining [12] . In HDLECs, LYVE-1 was shown by Johnson et al. [13] to exhibit a perinuclear staining pattern, co-localizing with markers of ER and Golgi where its de novo synthesis occurs. The exact subcellular localization of CRSBP-1/LYVE-1 in LECs is not clear. In this communication, we demonstrate that CRSBP-1 is localized to the plasma membrane as well as intracellular fibrillar structures. The CRSBP-1-associated fibrillar structure is identical to the ER network, as evidenced by its co-localization with binding immunoglobulin protein (BiP), an ER resident protein [14] . We also show that CRSBP-1 ligands stimulate contraction of CRSBP-1-associated ER network in a CRSBP-1-dependent and paclitaxelsensitive manner.
Materials and methods

Materials
PDGF peptide (a 19-mer peptide containing the amino acid sequence YVRVRRPPKGKHRKFKHTH) and VEGF peptide (a 25-mer peptide containing the amino acid sequence KKSVRGKGKGQKRKR KKSRYKSWSV) were synthesized by C S Bio Co. (Menlo Park, CA). Rabbit anti-CRSBP-1 antiserum was prepared as described [6, 9, 12] 
siRNA transfection
Transfection of SVEC4-10 cells with control siRNA and CRSBP-1 siRNA was performed according to the manufacturer's protocol (Santa Cruz Biotechnology) as previously described [12] . Briefly, cells grown on coverslips were washed once with transfection medium. Transfection medium (0.8 ml) (sc-36868) was added to the cells. A 0.2 ml aliquot of transfection medium containing 80 pmoles CRSBP-1 siRNA (sc-42902) or control siRNA (sc-37007) and 8 ll of transfection reagent (sc-29528) was incubated at room temperature for 30 min before adding to the cells. Following 48 h incubation at 37°C, transfected cells were washed and treated as described before.
Statistical analysis
The values are presented as means ± S.D. (n = 3-5). Two-tailed unpaired Student's t-test was used to determine the significance of differences between groups. P < 0.05 was considered significant.
Results
CRSBP-1 localizes to the plasma membrane and intracellular fibrillar structures in LECs
CRSBP-1 is known to be a cell-surface membrane protein but its subcellular localization in LECs has not been characterized. We previously generated H1299/CRSBP-1 cells for studying the cell biology of CRSBP-1 [9] . However, H1299 cells are a human lung carcinoma cell line and are not an ideal cell system for investigation of such properties of CRSBP-1 because CRSBP-1 is primarily localized to lymphatic capillary endothelial cells. For this reason, we identified SVEC4-10 cells as a candidate cell system for studying the cell biological functions of CRSBP-1. SVEC4-10 cells are a SV40-immortalized endothelial cell line derived from mouse axillary lymph nodes. These cells are thought to be derived from vascular endothelial cells [15, 16] . However, Western blot analysis of SVEC4-10 cell revealed that they express CRSBP-1, podoplanin, PDGFpR and VEGFR3 [12] . All of these proteins have been reported to be specific markers for lymphatic capillary endothelial cells [17] . SVEC4-10 cells also exhibit ultrastructural features characteristic of LECs including sparse microvillous surface projections, overlapping intercellular junctions and abundant intermediate filaments [16] . They are LEC-like cells.
To define the cell biological role of CRSBP-1, we examined subcellular localization of CRSBP-1 in SVEC4-10 cells by immunolocalization using rabbit antiserum to the cytoplasmic tail of CRSBP-1 (anti-CRSBP-1 serum) [6, 9, 12] . After fixation and permeabilization of SVEC4-10 cells, CRSBP-1 was visualized with fluorescence microscopy after incubation of the fixed cells with preimmune serum (Fig. 1, panel A) , anti-CRSBP-1 serum (Fig. 1, panel B) , or anti-CRSBP-1 serum with 2 mM CRSBP-1 peptide antigen [1] ( Fig. 1 , panels C) followed by incubation with FITC-conjugated goat anti-rabbit IgG. As shown in Fig. 1 (panel B) , CRSBP-1 is localized to the plasma membrane and also to intracellular fibrillar structures in SVEC4-10 cells. The fibrillar structures are not actin fibers, microtubules or intermediate filaments based on co-immunolocalization experiments (data not shown). In these cells, CRSBP-1 is associated with a fibrillar network extending from the perinuclear membrane to the leading edge of the plasma membrane ( 
CRSBP-1 ligands stimulate contraction of CRSBP-1-associated intracellular fibrillar structures in a time-dependent manner in LECs
To determine the functional significance of the association of CRSBP-1 with the fibrillar structures, we determined the effects of CRSBP-1 ligands (VEGF peptide and HA) on the CRSBP-1-associated fibrillar structures in SVEC4-10 cells. VEGF peptide, a 25-mer peptide containing the CRS motif of VEGF-A
165
, is a specific CRSBP-1 ligand which does not interact with VEGFR2 [1] . The cells were treated with VEGF peptide (2 lM) or HA (100 lg/ml). After 2 h at 37°C, the cells were fixed with methanol at À20°C for 10 min and stained with anti-CRSBP-1 serum followed by FITC-conjugated goat anti-rabbit IgG. In cells treated with VEGF peptide (Fig. 2) , the fibrillar structures became contracted as compared with the same structures in cells treated with vehicle only (Fig. 2 , panel D vs. panel C). HA, also a ligand for CRSBP-1, exhibited moderate effects on the morphology of SVEC4-10 cells, causing them to assume a spindle (fibroblast-like) appearance which was due to changes in the CRSBP-1-associated fibrillar structures (Fig. 2, panel E) . However, the effects of both HA and VEGF peptide were abolished when cells were co-treated with HA and VEGF peptide (Fig. 2, panel F) . The mechanism for this effect of co-treatment with HA and VEGF peptide is unknown, but VEGF peptide is known not to affect HA binding to CRSBP-1 [9] . This is likely due to an allosteric effect. The HA and CRS motif binding sites are located at distinct sites: the Link module (amino acid residues 54-130) and the acidic-amino-acidrich region (amino acid residues 204-229), respectively, in human CRSBP-1 [18] .
To determine the functional significance of the contraction of CRSBP-1-associated fibrillar structures in SVEC4-10 cells, we examined the time dependence of the effects of CRSBP-1 ligands (PDGF peptide, VEGF peptide and HA) on CRSBP-1-associated fibrillar structures. PDGF peptide, a 19-mer peptide containing the CRS motif of PDGF-BB, is a specific CRSBP-1 ligand and does not interact with the PDGF b-type receptor (PDGFbR) [1, 9] . SVEC4-10 cells were treated with PDGF peptide (10 lM), VEGF peptide (10 lM), or HA (100 lg /ml). After 0 h, 0.5 h, 1 h, and 2 h at 37°C, the cells were fixed with methanol at À20°C for 20 min and stained with rabbit antiserum to CRSBP-1 and rhodamine red-conjugated goat antirabbit IgG. The CRSBP-1-associated fibrillar structures appeared to be relatively stable and did not show any morphological changes after incubation with vehicle only at 37°C for 2 h (Fig. 3 , panel D vs. panel A). However, PDGF peptide, VEGF peptide and HA all stimulated maximal contraction of the fibrillar structures in SVEC4-10 cells after a 30-min incubation at 37°C (Fig. 3 , panels, F, J and N, respectively). CRSBP-1 ligand-stimulated contraction of the CRSBP-1-associated fibrillar structures was then quantified.
As shown in Fig. 4 (panel A), PDGF peptide at 10 lM for 0.5 h stimulated contraction of the fibrillar structures by $70%. Treatments with VEGF peptide (10 lM) and HA (100 lg/ml) for 0.5 h caused contraction of the fibrillar structures by $40% and $30%, respectively (Fig. 4 , panels B and C).
CRSBP-1 ligands stimulate contraction of the CRSBP-1-associated ER network in LECs
Since immunostaining of CRSBP-1 does not colocalize with that of any of the known cytoskeleton proteins and since the CRSBP-1-associated fibrillar structures include the perinuclear membrane which is known to be associated with the endoplasmic reticulum (ER) network, we hypothesized that CRSBP-1-associated fibrillar structures are identical to the ER network. To test this hypothesis, we determined the co-localization of CRSBP-1 and BiP, which is a heat shock protein and a specific marker for the ER [14] , using indirect immunofluorescence staining and confocal microscopy. As shown in Fig. 5A , the CRSBP-1-associated fibrillar structures colocalize with the staining pattern of BiP (panels A, B and C). While the immunostaining pattern of BiP lacked the plasma-membrane distribution, the intracellular staining pattern of BiP was completely identical to that of CRSBP-1 (panels C, F, I, L and O). To determine the effects of CRSBP-1 ligands on the CRSBP-1-associated ER network, SVEC4-10 cells were stimulated with 10 lM VEGF peptide, 10 lM PDGF peptide, 5 nM VEGF-A 165 , and 100 lg/ for LECs which express very little endogenous VEGFR2, a specific receptor for VEGF-A 165 in blood vascular endothelial cells [5, 19, 20] . These results suggest that CRSBP-1 ligands are capable of stimulating contraction of the CRSBP-1-associated ER network in SVEC4-10 cells.
As described above, SVEC4-10 cells are SV40-transformed LECs [16] . To determine if CRSBP-1 ligand-stimulated effects observed in SVEC4-10 cells also occur in normal LECs, we performed the same set of experiments using primary-culture HDLECs isolated from human skin (PromoCell C-12216). HDLECs grown on coverslips were stimulated with 10 lM VEGF peptide, 10 lM PDGF peptide, [1, 5, 19, 20] . These results suggest that CRSBP-1 is localized to the plasma membrane and the ER network in mouse and human LECs and that CRSBP-1 ligands stimulate contraction of the CRSBP-1-associated ER network in both cell types.
CRSBP-1 ligands stimulate contraction of the CRSBP-1-associated ER network in a CRSBP-1-dependent manner in SVEC4-10 cells
To test the involvement of CRSBP-1 in ligand-stimulated contraction of the ER network, SVEC4-10 cells were transfected with control siRNA or CRSBP-1 siRNA as described previously [12] .
These transfected cells were then treated with 10 lM of PDGF peptide or VEGF peptide for 1 h and then analyzed by indirect immunofluorescence staining using antiserum to CRSBP-1 and antibody to BiP. As shown in Fig. 6 , cells transfected with control siRNA, like untransfected cells, exhibited responses to ligandstimulated contraction of the CRSBP-1-associated ER network (panels D, E, F and panels G, H, I vs. panels A, B, C). However, down-regulation of CRSBP-1 expression by transfection of cells with CRSBP-1 siRNA abolished such ligand-stimulated contraction (Fig. 6 , panels M, N, O and P, Q, R vs. panels J, K, L). Under the stated conditions [12] , at 48 h after CRSBP-1 siRNA transfection, CRSBP-1 protein levels were down-regulated by $80% compared with levels in cells transfected with control siRNA. Interestingly, downregulation of CRSBP-1 proteins by CRSBP-1 siRNA transfection also led to constitutive contraction of the ER network (panels J to R vs. panels A, B and C). These results suggest that CRSBP-1 is required for ligand-stimulated contraction of the ER network in SVEC4-10 cells. These results are also comparable to our recent findings that CRSBP-1 siRNA transfection abolishes ligand-stimulated permeability in SVEC4-10 cell monolayers and that down-regulation of CRSBP-1 protein by CRSBP-1 siRNA transfection leads to constitutively increased permeability in these cells [12] . contraction of the ER network in these cells (panels M, N, O and panels P, Q, R vs. panels D, E, F and panels G, H, I). Paclitaxel alone did not affect the ER network (panels J, K and L vs. panels A, B and C). These results suggest that PDGF peptide and VEGF peptide stimulate contraction of the ER network in SVEC4-10 cells in a paclitaxel-sensitive manner.
Discussion
The subcellular localization of CRSBP-1 in the plasma membrane and ER network suggests a unique property of CRSBP-1. Many type I membrane proteins are mainly localized in the plasma membrane and are not detected in the ER even though they traffic through it to the plasma membrane after synthesis. The ER retention mechanism of CRSBP-1 is unknown. CRSBP-1 does not contain the C-terminal di-lysine or di-arginine motif which has been shown to mediate ER retention of type I membrane proteins [26] . However, it contains a basic amino acid-rich motif (KSPSKTTVR) near its C-terminus. This motif is well conserved in all known mammalian CRSBP-1 congeners and may play a role in the ER localization of mammalian CRSBP-1 congeners (human, bovine and mouse). The functional significance of ER localization of CRSBP-1 in ligand-stimulated contraction of LECs is not known. Several lines of evidence indicate that ER localization of CRSBP-1 plays an important role in CRSBP-1 ligand-stimulated LEC contraction. These include: (1) CRSBP-1 ligands are unable to stimulate detectable contraction in SSV-transformed cells and H1299/ CRSBP-1 cells, both of which express CRSBP-1 but do not exhibit the ER localization of CRSBP-1 [6, 9] . (2) A specific kinase activity inhibitor of PDGFbR, which is a signaling partner of CRSBP-1, inhibits CRSBP-1 ligand-stimulated contraction in LECs [12] . This suggests that CRSBP-1 ligand-stimulated contraction of the CRSBP-1-associated ER network is a downstream effect of the CRSBP-1-PDGFbR-mediated signaling [12] and (3) Contraction of the ER network is known to be associated with morphological changes in cells [23, 24] . The localization and abundance of CRSBP-1 at both the plasma membrane and ER may explain why lymphatic endothelium in tissues can be strongly stained histochemically by anti-CRSBP-1 antibody.
The CRSBP-1 ligand-induced contraction of the ER network appears to be mediated by microtubules as evidenced by the observation that paclitaxel, a microtubule polymer stabilizer, effectively blocks CRSBP-1 ligand-induced contraction of the ER network. Since microtubule contraction is commonly associated with morphological changes in cells [21] [22] [23] [24] , we predicted that CRSBP-1 ligand-induced contraction of the ER network in SVEC4-10 cells and HDLECs would result in morphological changes in these cells. As predicted, we found that CRSBP-1 ligand stimulation does result in morphological (opening of intercellular junctions) and functional changes (increased permeability) at intercellular junctions in these LEC monolayers. The finding of paclitaxel as a potent inhibitor for CRSBP-1 ligand-stimulated contraction of CRSBP-1 ligand-associated ER network (and likely for CRSBP-1 ligand-stimulated opening of lymphatic intercellular junctions as well) [12] has potentially important clinical implications. Physiological CRSBP-1 ligands (e.g., PDGF-BB) are hypothesized to be utilized by carcinoma cells in the interstitial space of tissues to enter lymphatic vessel lumens by inducing opening of lymphatic intercellular junctions during lymphatic metastasis. Paclitaxel and related compounds may prevent lymphatic metastasis in certain human cancers (e.g., lung cancer) [27] by blocking CRSBP-1 ligand-induced opening of lymphatic intercellular junctions. Johnson et al. [13] demonstrated that most of the LYVE-1 (or CRSBP-1) intracellular staining is lost upon stimulation of HDLECs with TNF-a. This raises the possibility that CRSBP-1 ligands might induce contraction (or shortening) of CRSBP-1-asosciated ER network by down-regulating the cell-surface and intracellular levels of CRSBP-1, by analogy to the effect of TNF-a. However, we found that treatment with CRSBP-1 ligands does not diminish the cell-surface and total protein levels of CRSBP-1 in SVEC4-10 cells [28] . In contrast, TNF-a completely down-regulates cell-surface expression of CRSBP-1 in SVEC4-10 cells [28] , as reported by Johnson et al. in HDLECs [13] . These results suggest that the effects of CRSBP-1 ligands on CRSBP-1/LYVE-1 expression are distinct from those of TNF-a in LECs. Here we demonstrate that down-regulation of CRBP-1 protein by transfection with CRSBP-1 siRNA abolishes lignd-stimulated contraction of the ER network in SVEC4-10 cells and that these cells transfected with CRSBP-1 siRNA exhibit constitutive contraction of the ER network. Together with previous observations [10, 12] , these results suggest that CRSBP-1 ligands stimulate contraction of the ER network and LECs in a CRSBP-1-dependent manner, resulting in opening of lymphatic intercellular junctions. This leads to increased permeability in LEC monolayers in vitro and increased interstitial-lymphatic transit in whole animals. Down-regulation of CRSBP-1 protein by transfection of cells with CRSBP-1 siRNA and CRSBP-1-null mutation in mice cause constitutive contraction of LECs and constitutively increased permeability in LEC monolayers, and formation of distended lymphatic vessel lumens (opening) and constitutive increase in interstitial-lymphatic transit in whole animals, respectively [10, 12] . LYVE-1 (CRSBP-1) is involved in the formation of VEcadherin-mediated ''button''-like structures at lymphatic intercellular junctions [11] . These results also support the hypothesis that CRSBP-1 siRNA transfection/CRSBP-1-null mutation and binding of CRSBP-1 by its cognate ligands result in loss and ''unbuttoning'' of VE-cadherin-mediated buttons, respectively, leading to opening of lymphatic intercellular junctions [10, 12] .
